Definition
Parkinson’s disease (PD): a syndrome defined in life by clinical criteria involving tremor at rest, rigidity, slowness and paucity of movement, and altered posture, gait, and balance with the absence of “atypical” features (Lang and Lozano 1998a,b). It is defined at autopsy by strict pathological criteria including the loss of neurons in the pars compacta of the substantia nigra, locus ceruleus and dorsal motor nucleus of the vagal nerve, and the presence of Lewy bodies.
Pharmacological Properties
Although Parkinson’s disease (PD) is classified as a “movement disorder,” it should also be considered a “neurobehavioral” disorder. The diagnosis of PD is based on the presence of clinical criteria having to do purely with movements and the absence of exclusionary or atypical features such as dementia, hallucinations, and corticospinal track findings (Lang and Lozano 1998a, b). The only objective study of value is the DaT (dopamine transporter) scan which identifies a dopamine...
This is a preview of subscription content, log in via an institution to check access.
References
Burn D, Emre M, McKeith I et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 21(11):1899–1907
Constantinescu R, Romer M, McDermott MP et al (2007) Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 22(9):1317–1319
Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276(7):374–379
Cummings J, Isaacson S, Mills R, et al (2013) Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson’s disease psychosis (ACP-103-020). World Parkinson Disease Congress, Montreal, Oct 2013
Fox SH, Lang AE (2008) Levodopa related motor complications-phenomenology. Mov Disord 23(Suppl 3):S509–S514
Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 21(8):677–692
Lang AE, Lozano AM (1998a) Parkinson’s disease part 1. N Engl J Med 339(15):1044–53
Lang AE, Lozano AM (1998b) Parkinson’s disease part 2. N Engl J Med 339(16):1130–43
Menza M, Dobkin RD, Marin H et al (2009) A controlled trial of anti-depressants in patients with Parkinson’s disease. Neurology 72(10):886–892
Miyasaki JM, Shannon K, Voon V et al (2006) Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson’s disease (an evidence based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 66(7):996–1002
Pahwa R, Factor SA, Lyons KE et al (2006) Practice parameter: treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidenced base review): report of the quality standards subcommittee of the American academy of neurology. Neurology 66(7):983–995
Parkinson Study Group (1999) Low dose clozapine for the treatment of drug induced psychosis in Parkinson’s disease. N Engl J Med 340(10):757–763
Richard IH, McDermott MP, Kurlan R et al (2012) A randomized double blind placebo controlled trial of antidepressants in Parkinson’s disease. Neurology 78(16):1229–1236
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Friedman, J.H. (2013). Anti-Parkinson Drugs. In: Stolerman, I., Price, L. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27772-6_34-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27772-6_34-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27772-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences